Bionano launches optical genome mapping tests for prenatal, postnatal analysis
Sean Anthony Eddy
- Bionano Genomics' (NASDAQ:BNGO) unit Bionano Laboratories launched two new laboratory developed tests (LDTs) based on optical genome mapping (OGM).
- The two tests, OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV, offer a genome-wide assessment of structural variants (SVs) and provide testing for most common and rare chromosomal abnormalities, according to Bionano.
- The company noted that the OGM-Dx Postnatal Whole Genome SV tests peripheral blood samples from people diagnosed with autism spectrum disorder (ASD), intellectual disability, developmental delay, epilepsy and rare undiagnosed genetic diseases. The report will include a whole genome analysis of SVs and will screen for the common CGG expansion in the FMR1 gene which may suggest Fragile X syndrome.
- Meanwhile, OGM-Dx Prenatal Whole Genome SV may be used for fetuses where a genetic anomaly is suspected.
- "These LDTs are designed to provide a comprehensive evaluation of genome wide SVs that we believe will assist clinicians in assessing the best potential medical management for their patients," said Justin Leighton, vice president of laboratory business at Bionano Laboratories.